Provider Ranking · FDA Label–Verified · May 2026
Best GLP-1 Provider for Statin Users (2026): Verified Picks That Actually Read Your Medication List
Affiliate disclosure: we may earn a commission when you start a program through some of the links below. That does not change your price, and it does not change our rankings. On this page, evidence and fit beat payout.
If you take a statin and you are trying to pick the right online GLP-1 program, this is the page we wish existed when our team started looking into it.
The short answer: for most people searching for the best GLP-1 provider for statin users, Ro is the strongest first path to compare. Ro's clinicians order metabolic lab testing through Quest when clinically indicated, the program carries the leading FDA-approved GLP-1 lineup for weight care — Foundayo™, Wegovy® pen, Wegovy® pill, Zepbound® pen, and Zepbound® KwikPen — and the insurance concierge handles prior authorization paperwork for you.
If you'd rather pick your own clinician or use Costco's cash price on Wegovy or Ozempic, Sesame Care is the strongest runner-up. Labs are included in most states, and the formulary covers the broadest list of FDA-approved GLP-1 options across major telehealth platforms.
If you're paying cash and your statin is just for high cholesterol — no heart attack, no stroke, no stent — Enhance.MD or Eden can work. We'll show you which fits which situation.
Now here's the part nobody else is telling you. The right provider for a statin user has almost nothing to do with the statin itself. It has everything to do with why you take it. And there's one specific GLP-1–statin interaction every other comparison page is quietly ignoring.
What we actually verified for this page
Quick Decision Table: Which Path Fits You in 30 Seconds
| Your situation | Best first path | Why | Next step |
|---|---|---|---|
| Statin because of a heart attack, stroke, stent, bypass, or diagnosed heart disease AND you have overweight or obesity | Ro | FDA-approved GLP-1 path including Wegovy + free insurance coverage check + concierge handles prior auth | Check Ro coverage → |
| Statin for high cholesterol only and want insurance to cover Wegovy or Zepbound | Ro | Insurance concierge is the strongest in this space; clinicians order labs through Quest when needed | Check Ro coverage → |
| Want to pick your specific clinician or use Costco pricing on branded Wegovy or Ozempic | Sesame Care | Provider choice, labs in most states, Costco/Novo partnership: $349/month for Wegovy or Ozempic, first 2 months at $199 for qualifying new patients (valid through June 30, 2026) | See Sesame Care → |
| Paying cash and want labs included in the program | Enhance.MD | Metabolic lab testing every 6 months built into the program; honest disclosure that medications are compounded | See Enhance.MD → |
| Paying cash and want the lowest first-month entry | Eden | Compounded semaglutide from $129 first month on a 3-month plan; HSA/FSA eligible | See Eden → |
| Not sure which bucket you're in | Take our quiz | 60-second matching quiz routes you based on your statin, heart risk, insurance, and budget | Get my GLP-1 path → |
If MEDVi's pricing caught your attention elsewhere, read the MEDVi section before you click anything.
Can You Take a GLP-1 With Your Statin? (Yes — Here's the Research)
1Layer 1: The Pharmacokinetic Study
In 2017, researchers gave 26 healthy adults a 40 mg dose of atorvastatin both with and without semaglutide. They measured total drug exposure (AUC) and peak blood level.
Total atorvastatin exposure was unchanged. The ratio came out to 1.02 — well inside the 0.80–1.25 range the FDA uses to define "no effect." Peak blood level dropped 38%, but that does not matter for statins. Statins work by blocking an enzyme in your liver over time, not by hitting a high peak. The study tested metformin, warfarin, and digoxin too — same conclusion.
Source: Hausner et al., Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects, Clinical Pharmacokinetics, 2017.
2Layer 2: The Wegovy Prescribing Label
The FDA-approved Wegovy label, supported by NovoMedLink, indicates no required dose adjustment with statins, antibiotics, or oral contraceptives. The same label notes that Wegovy delays gastric emptying and may affect the absorption of oral medications, which is why your provider should still see your full medication list before prescribing.
3Layer 3: The SELECT Trial — The One That Matters Most for Statin Users
Half got semaglutide 2.4 mg once weekly (the Wegovy dose). Half got placebo. The headline result: a 20% reduction in cardiovascular death, non-fatal heart attack, or non-fatal stroke. The FDA used these results to approve Wegovy for cardiovascular risk reduction in March 2024.
Sources: Lincoff et al., New England Journal of Medicine, 2023; American College of Cardiology SELECT trial summary; FDA press release, March 8, 2024.
A Statin Interaction Evidence Ladder
| Combination | Evidence | What it means in practice |
|---|---|---|
| Semaglutide + atorvastatin | 2017 pharmacokinetic study; AUC unchanged | No dose adjustment expected |
| Wegovy + statins generally | NovoMedLink prescribing information | No restrictions or required dose adjustments listed; gastric emptying may still affect oral absorption |
| Foundayo + atorvastatin | Lilly Medical | No clinically relevant changes reported |
| Foundayo + rosuvastatin | Lilly Medical | No clinically relevant changes reported |
| Foundayo + simvastatin | Lilly Medical / Foundayo prescribing information | Do not exceed 20 mg simvastatin once daily |
| Semaglutide / Wegovy + statins in SELECT (17,604-patient trial) | Lincoff et al., NEJM 2023 | 20% reduction in major cardiovascular events, on top of statin therapy |
The Statin-User GLP-1 Provider Fit Matrix
This is the comparison no other page builds. We scored five major GLP-1 telehealth providers on the seven things that actually matter when you are already on a cardiovascular medication. Verified May 8, 2026.
| Criterion | Ro Body | Sesame Care | Enhance.MD | Eden | MEDVi |
|---|---|---|---|---|---|
| Asks for current medications during intake | ✅ Detailed | ✅ Detailed | ✅ Yes | ✅ Yes | ✅ Yes |
| Baseline lipid panel included | ⚠️ Provider-ordered Quest; at-home kit may cost $75 | ✅ Included most states (excl. AZ, HI, ND, NJ, NY, OK, RI, SD, WY) | ✅ Lab schedule built into program | ❌ Not routinely required | ❌ Not standard |
| Kidney function check (creatinine, eGFR) | ✅ Included when labs ordered | ⚠️ Provider-driven | ⚠️ Conditional on schedule | ❌ Not routinely | ❌ Not standard |
| Ongoing lipid monitoring after start | ✅ Repeat labs at provider's call | ⚠️ Provider-driven | ✅ Built-in lab schedule | ⚠️ At provider discretion | ❌ Not built-in |
| Insurance / prior auth support | ✅ Concierge + free GLP-1 Coverage Checker (private + FEHB) | ✅ Provider-driven PA + Costco/Novo partnership | ❌ Cash-pay only | ❌ Cash-pay only | ❌ Cash-pay only |
| FDA-approved brand options (Wegovy has CV event-reduction indication) | ✅ Foundayo, Wegovy pen/pill, Zepbound pen/KwikPen, Ozempic | ✅ Multiple FDA-approved weight-loss and diabetes-labeled options | ❌ Compounded only (per Enhance.MD disclosure) | ⚠️ Branded available alongside compounded | ❌ Compounded focus + active FDA warning letter |
| Statin-aware clinical workflow | ✅ Lab kit checks lipids; concierge can route private insurance | ✅ Provider review captures full med history | ⚠️ Standard intake | ⚠️ Standard intake | ⚠️ Under FDA scrutiny |
| Best fit for statin users | Insured users, CVD history, Wegovy CV indication, prior auth needs | Provider choice, Costco pricing, branded self-pay | Cash-pay, lab-forward, no CVD | Lowest first-month cash-pay entry | Not our lead pick on this page |
Editorial scoring note: this is a provider-fit ranking, not a clinical safety score. We scored each provider on publicly verifiable criteria that matter most to people already taking a cardiovascular medication. Verified May 8, 2026.
Ro is the strongest combined fit — FDA-approved options, insurance checking, prior auth support, and provider-ordered lab testing.
Is Ro the Best GLP-1 Provider for Statin Users?
Pricing you can actually plan around
Medication billed separately. Branded GLP-1 prices on Ro listed as matching LillyDirect, NovoCare, and TrumpRx.
But for a statin user — especially one with any heart history — paying $149/month for a program that pairs FDA-approved medication with insurance coordination is usually a better deal.
What Ro states the program includes
- Provider-ordered lab testing. Quest testing included when ordered; at-home blood collection kit listed at $75 (or shipped at no extra cost in states where Quest access is unavailable). For a statin user, the lipid panel, A1C, thyroid, and kidney markers are exactly the panel you want.
- Video visit with a Ro-affiliated clinician to review labs, your full medication list, and your goals.
- FDA-approved formulary: Foundayo, Wegovy pen, Wegovy pill, Zepbound pen, Zepbound KwikPen, and Ozempic.
- Free GLP-1 Insurance Coverage Checker. Enter your insurance info and get a personalized coverage report before committing.
- Insurance concierge. If your medication needs prior authorization (most insured Wegovy and Zepbound prescriptions), Ro's team handles the paperwork. You don't fax anything.
- Provider messaging, dose adjustments, and ongoing nurse coaching through the program.
A limitation worth knowing
Ro states it cannot help coordinate GLP-1 coverage for government insurance plans, with an exception for FEHB plans. If you have Medicare, Medicaid, TRICARE, or VA coverage, verify GLP-1 coverage directly with your plan.
Who Ro is best for
- Statin because of established CVD (heart attack, stroke, stent, bypass, PAD) and you have overweight/obesity
- Private insurance or FEHB and want prior auth handled
- You want FDA-approved medication, not compounded
- You want labs ordered through your provider workflow without booking a separate appointment
Skip Ro if
- Your only goal is the lowest possible cash-pay price on a compounded medication
- You have Medicare, Medicaid, TRICARE, or VA (Ro cannot coordinate for those)
If FDA-approved medication and insurance support are what you need:
Is Sesame Care a Better Fit If You Want Provider Choice or Costco Pricing?
Most GLP-1 telehealth platforms assign you whoever's available. Sesame lets you browse providers, read patient reviews, and pick the one you want. For statin users who want a clinician with experience in cardiovascular medication management, that matters.
The Costco/Novo Nordisk Partnership (valid through June 30, 2026 per Sesame's FAQ)
No insurance required (clinical appropriateness still required). For a statin user who can't get insurance coverage but still wants FDA-approved medication, this beats almost everything except direct manufacturer pricing.
Is Enhance.MD the Best Cash-Pay GLP-1 Provider With Labs Included?
| Program | Commitment | First month | Ongoing | What's included |
|---|---|---|---|---|
| GLP-1 Core (compounded semaglutide) | 12-month | $49 | $212/month | Provider care, labs every 6 months |
| GLP-1 Advanced (compounded tirzepatide) | 12-month | $99 | $280/month | Provider care, labs every 6 months |
| GLP-1 Elite (provider-prescribed compounded) | 12-month | $189 | $322/month | Provider care, labs every 6 months |
Enhance.MD is best for
- Statin is for high cholesterol or primary prevention — no prior heart attack, stroke, or stent
- Paying cash and value lab monitoring
- You understand and accept the compounded-medication tradeoff
Skip Enhance.MD if
- You have established cardiovascular disease — the Wegovy FDA cardiovascular indication is for the FDA-approved branded version, not compounded semaglutide. If you've had a heart event, start your comparison with the medicine that has the outcome evidence.
Is Eden the Best Low-Cost Cash-Pay GLP-1 Option?
| Plan | First month | Ongoing |
|---|---|---|
| Compounded semaglutide, 3-month plan | $129 | $209/month after |
| Compounded semaglutide, monthly plan | $149 | $229/month after |
| GLP-1 treatments range | From $129 first month | Varies by medication and plan |
Should Statin Users Choose MEDVi Right Now?
Read this before clicking
On February 20, 2026, the FDA issued MEDVi a warning letter about false or misleading marketing claims related to compounded semaglutide and tirzepatide products. The FDA specifically objected to language suggesting compounded products were equivalent to FDA-approved drugs. In March 2026, the FDA expanded this enforcement. We re-checked MEDVi's warning letter status on May 8, 2026; it was still active as of that verification.
MEDVi has attractive cash-pay pricing — semaglutide at $179 first month, $299 refills. On price alone, it's competitive. But on a page about combining GLP-1 medication with cardiovascular drugs, leading with a provider currently under FDA scrutiny would be irresponsible.
If you're considering MEDVi anyway, ask them in writing before you pay:
- Which pharmacy will fill my prescription?
- Is the pharmacy state-licensed?
- What exact formulation will I receive?
- What's the cancellation policy?
- Will a clinician review my statin and dose before prescribing?
- What's the protocol if medication arrives warm or insufficiently refrigerated?
If you can't get clear answers, choose a different provider. Ro and Sesame both answer those questions on their public pages.
Why Your Reason for Taking a Statin Matters More Than Which Statin You Take
Group 1You take a statin for primary prevention
You've never had a heart attack, stroke, stent, or bypass. Your doctor put you on a statin because your LDL is high, you have a strong family history, multiple risk factors, or a high 10-year cardiovascular risk score.
Any of the providers in our matrix can work — the choice depends more on whether you want insurance help (Ro), provider choice (Sesame), labs included (Ro, Sesame, Enhance.MD), or the lowest cash-pay price (Eden, Enhance.MD).
Group 2You take a statin because you already have heart disease
This means you've had at least one of: a heart attack, a stroke, a stent or bypass surgery, diagnosed coronary artery disease, peripheral artery disease, or a cardiologist who manages your care.
Compounded GLP-1s do not carry this indication. For Group 2, Ro is the strongest first path. Sesame Care is the strong runner-up.
Group 3You can't tolerate statins
If you've stopped or switched statins because of side effects, a GLP-1 is not a replacement for a statin. GLP-1 medications can improve lipid markers, but the effect is usually smaller than statin-level LDL lowering. Per AHA/ACC guidance, moderate-intensity statins lower LDL-C by 30%–49% and high-intensity statins lower it by 50% or more.
The right next step if you can't tolerate a statin is a conversation with your prescriber about alternatives like ezetimibe, bempedoic acid (Nexletol), or PCSK9 inhibitors — not switching to a GLP-1 alone for cholesterol management. A GLP-1 may still be appropriate for weight loss and cardiovascular risk reduction in this group, but it's an addition, not a replacement.
Not sure which group you're in? Take our free 60-second quiz — we'll route you based on your statin reason, heart history, insurance, and budget.
Get my personalized GLP-1 path → No email requiredWhat Is the Foundayo + Simvastatin Interaction?
| If you take... | Foundayo prescribing guidance |
|---|---|
| Simvastatin (Zocor) | Do not exceed 20 mg of simvastatin once daily |
| Atorvastatin (Lipitor) | No clinically relevant changes observed (per Lilly Medical) |
| Rosuvastatin (Crestor) | No clinically relevant changes observed (per Lilly Medical) |
| Other statins (pravastatin, pitavastatin, lovastatin) | Not specifically addressed in current public guidance — ask your provider |
| Oral hormonal contraceptives | Use non-oral contraception or add a barrier method for 30 days after starting Foundayo and after each dose escalation |
If you're on simvastatin at 40 mg or 80 mg per day and you're considering Foundayo, your prescriber may either lower your simvastatin dose, switch you to a different statin (atorvastatin or rosuvastatin), or recommend an injectable GLP-1 instead. This is exactly why a provider that actually reads your medication list matters.
Ro and Sesame Care both ask for current medications and dosages during intake. Eden, Enhance.MD, and MEDVi also ask, but their intake quality varies by visit.
Sources: Foundayo (orforglipron) prescribing information; Lilly Medical clinical pharmacology guidance, current 2026.
The "Should I Loop In My Cardiologist?" Decision Framework
You probably do NOT need to
- You take a statin for primary prevention (no heart event history)
- Your most recent lipid panel is on-target for your risk level
- Your primary care doctor manages your statin
- You're starting a GLP-1 with a provider that runs labs (Ro, Sesame, Enhance.MD)
You SHOULD loop in your cardiologist if
- You have established cardiovascular disease (prior heart attack, stroke, stent, bypass, PAD)
- You see a cardiologist regularly and they manage your statin
- Your lipid numbers aren't where your cardiologist wants them yet
- You take a complex regimen (statin + blood pressure + blood thinner + others)
- You're considering Wegovy specifically for the cardiovascular benefit
A simple message to send your cardiologist if you're in that bucket:
"I'm thinking about starting a GLP-1 medication for weight loss through [Ro / Sesame Care / etc.]. The program will review my full medication list, including my statin, and order baseline labs. Is there anything you want to flag before I start, or would you prefer I share my labs with you first?"
Most cardiologists welcome this. The combination is well-studied. They'd rather know than not.
Will Insurance Cover a GLP-1 If I Take a Statin?
What insurance companies generally look for
- BMI ≥ 30 (obesity) OR BMI ≥ 27 with at least one weight-related condition
- Documentation of prior weight-loss attempts
- Prior authorization paperwork from your prescriber
If you have established cardiovascular disease and overweight or obesity, some plans now cover Wegovy specifically for its cardiovascular indication even when they don't cover other GLP-1s for weight loss.
Cash-pay reality check
What About Wegovy's Heart-Disease Approval?
This indication applies to
- Adults with established CVD (prior heart attack, stroke, PAD, or coronary artery disease)
- AND obesity or overweight (BMI thresholds apply)
SELECT enrolled adults aged 45+ with BMI ≥27 and established CVD.
This does NOT mean
- Every statin user should switch to Wegovy
- Compounded semaglutide gives you the same cardiovascular benefit (it doesn't — the FDA has not reviewed compounded versions)
- You should stop your statin (you should not)
- Wegovy replaces blood pressure medications, blood thinners, or other heart medications
If you've already had a heart event and have overweight or obesity, the FDA recognizes Wegovy specifically as a tool that, on top of your existing statin and other heart medications, reduces your risk of another event. This is why we lead this page with Ro for that group of readers.
A Note About the FDA's April 30, 2026 Compounded GLP-1 Proposal
On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Public comments are due June 29, 2026.
In plain English: 503B is the category of larger-scale compounding pharmacies. If the FDA finalizes this proposal, some pathways for compounded GLP-1 supply may change. The regulatory landscape is actively shifting.
If you're considering a compounded GLP-1 path (Eden, Enhance.MD, MEDVi, or others), this is worth checking on monthly. We re-verify it as part of our standard recency review for this page.
The Statin User's Pre-Visit Checklist
Whichever provider you pick, walking into the intake with this information ready will get you a better visit.
What to gather before your video visit
- Your statin name and exact dose (e.g., atorvastatin 40 mg)
- Why you take a statin (high cholesterol, prior heart event, etc.)
- Most recent lipid panel if you have it (LDL, HDL, triglycerides, date)
- Most recent A1C or fasting glucose if available
- All other prescription medications with doses
- Over-the-counter medications and supplements you take regularly
- Heart history: any heart attack, stroke, stent, bypass, or chest pain workup
- Family history: heart attack or stroke in first-degree relatives, especially before age 55 (men) or 65 (women)
- Pregnancy status if applicable, plus oral contraceptive use (relevant if Foundayo is on the table)
- Personal or family history of medullary thyroid carcinoma or MEN2 (GLP-1 contraindication)
- Pancreatitis history, gallbladder issues, or severe GI conditions like gastroparesis
- Insurance card and pharmacy information
Red flags to watch for in the program itself
A trustworthy provider WILL:
- Ask for your full medication list with doses
- Clearly distinguish FDA-approved and compounded options
- Tell you which pharmacy fills your prescription
- Have a written cancellation policy
- Disclose pricing past the first month
Give you pause if they:
- Don't ask what other medications you take
- Use phrases like "same active ingredient as Wegovy" for compounded products (the exact language cited in the MEDVi warning letter)
- Won't tell you the pharmacy or confirm it's state-licensed
- Make you pay before any clinician reviews your case
- Sell by vial or syringe without clear written dosing instructions
Real Talk: What GLP-1s Actually Do for Cholesterol (And What They Don't)
The cholesterol improvement on GLP-1s mostly comes from the weight loss, with some direct effects on liver lipid metabolism. As your weight drops over months on a GLP-1, your provider may see triglyceride improvements first, with modest LDL improvements over time and possible HDL improvements. Inflammation markers like hs-CRP also tend to drop in clinical trials.
What this means in practice: if your statin has gotten your LDL on-target, it stays on-target. If you've been struggling, the GLP-1 may help — but it's additive to your statin, not a replacement.
Some patients on a GLP-1 eventually have their statin dose adjusted by their prescribing doctor based on serial lipid panels. That decision belongs to your statin prescriber — not your GLP-1 telehealth provider.
Frequently Asked Questions
How We Built This Comparison
Who we are: The Weight Loss Provider Guide editorial team — an independent comparison resource for GLP-1 telehealth providers. We are not a medical practice. We do not prescribe medication. We do not provide medical advice.
How we ranked providers
We scored each major GLP-1 telehealth provider on seven criteria specifically relevant to people taking a statin:
- Whether the intake actually asks for current medications and doses
- Whether a baseline lipid panel is included or readily ordered in the program
- Whether kidney function is checked
- Whether ongoing lipid monitoring is built into the program
- Whether insurance and prior authorization support is available
- Whether the provider carries FDA-approved brand options (with Wegovy carrying the cardiovascular event-reduction indication)
- Whether the program has a statin-aware clinical workflow
We weighted these criteria based on what statin users actually need — not based on which provider pays us the highest commission.
What we did NOT do
- • Did not medically clear any reader for any medication
- • Did not claim compounded medications are FDA-approved
- • Did not use customer testimonials as evidence of effectiveness
- • Did not rank providers by affiliate payout when evidence pointed elsewhere
- • Did not include MEDVi as a top pick despite competitive pricing because of the active FDA warning letter
Affiliate disclosure
When you start a program through some of the links on this page, we may earn a commission. That doesn't change your price. It doesn't change our rankings — Ro is our top pick because the evidence and feature set support it, not because of payout.
What Is the Best GLP-1 Provider for Statin Users? Our Final Verdict
#1: Ro — the strongest first path for most statin users
The only program in the matrix that combines provider-ordered lab testing with the leading FDA-approved GLP-1 formulary for weight care, runs a free GLP-1 Insurance Coverage Checker, and has an insurance concierge that handles prior authorization paperwork. Get started for $39, then as low as $74/month with annual plan paid upfront.
Check your eligibility on Ro →#2: Sesame Care — best if you want provider choice or Costco pricing
Costco/Novo partnership: $349/month for Wegovy or Ozempic, first two months at $199 for qualifying new patients (valid through June 30, 2026). Labs included in most states.
See Sesame Care's program →If you're paying cash and your statin is just for high cholesterol — no heart event:
Still Not Sure Which GLP-1 Program Is Right for You?
Take our free 60-second matching quiz. We'll route you based on your statin, your heart history, your insurance status, and your budget — and show you the right next step.
Get my personalized GLP-1 path →No email requiredAbout this page
Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We earn a commission on certain links and disclose every affiliate relationship. This page is for informational purposes only. It is not medical advice. Compounded GLP-1 medications are not FDA-approved. Wegovy®, Ozempic®, Zepbound®, Mounjaro®, Foundayo™, Saxenda® are registered or pending trademarks of their respective manufacturers.
Last verified: . We re-verify this page monthly.
Sources cited on this page
- Lincoff et al., New England Journal of Medicine, 2023 — SELECT trial primary publication
- Hausner et al., Clinical Pharmacokinetics, 2017 — semaglutide + atorvastatin pharmacokinetic study
- FDA press release, March 8, 2024 — Wegovy cardiovascular risk reduction approval
- Foundayo (orforglipron) prescribing information — Lilly Medical, 2026 (simvastatin cap, contraceptive guidance)
- NovoMedLink Wegovy prescribing information — no dose adjustment required with statins
- FDA warning letter to MEDVi, LLC, February 20, 2026 (fda.gov)
- FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list, April 30, 2026
- American College of Cardiology SELECT trial summary (acc.org)
- AHA/ACC guidance on statin intensity and LDL-C reduction targets
- Provider verification (May 7–8, 2026): ro.co/weight-loss, sesamecare.com, enhance.md, tryeden.com, glp.medvi.org